title: [Focus on beta-blockers for vascular specialists in 2012].
abstract: Since they were launched on the market in 1964, cardiovascular indications for beta-blockers have been validated and accepted worldwide. Numerous studies and meta-analysis have confirmed their benefits. They reduce mortality in post infarction and acute coronary syndrome populations and also in people with stable coronary heart disease. Moreover, heart failure with systolic left ventricular dysfunction is a major indication for this therapeutic class, providing a 30% decrease in mortality. In patients with permanent atrial fibrillation, beta-blockers are recommended for rate control. In hypertension patients, first-line drug treatment with beta-blockers is currently discussed. Indeed, several studies have shown that patients randomized in the beta-blocker arms experienced more coronary heart and cerebrovascular diseases than comparators. Their lesser effect on central blood pressure decrease could partially explain those results. Nevertheless, beta-blockers are still considered as first-line drugs for hypertension in the French and European guidelines. Long-term comparative studies focusing on central blood pressure are needed. Concerning the other indications for beta-blockers in vascular diseases, their use perioperatively to reduce surgical cardiovascular risk raised much hope, but the most recent results are disappointed and even suggest possible higher mortality. Finally, except for patients with critical ischemia of the lower limbs, presence of peripheral artery disease should probably be considered as a condition favoring their prescription.
authors.affiliation: Unité d'Hypertension Artérielle, Prévention et Thérapeutique Cardiovasculaires, Centre de Diagnostic et de Thérapeutique, Université Paris-Descartes, Hôtel-Dieu, AP-HP, place du Parvis-Notre-Dame, 75004 Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Mairesse
authors.forename: J
authors.initials: J
authors.lastname: Blacher
authors.forename: M-E
authors.initials: ME
authors.lastname: Safar
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000401:mortality; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000401:mortality; D000075202:Contraindications; D003327:Coronary Disease / Q000188:drug therapy / Q000401:mortality; D005260:Female; D006333:Heart Failure; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D059035:Perioperative Period; D012307:Risk Factors; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000401:mortality
chemical_list: D000319:Adrenergic beta-Antagonists